Sotheby's International Realty Leads the Industry Once Again in RealTrends Verified + The Thousand Rankings
NEW YORK, June 6, 2025 /PRNewswire/ -- Sotheby's International Realty is proud to share that it has once again secured its position as the real estate brand with the most agents represented on the 2025 RealTrends Verified + The Thousand Individuals by Sales Volume list, further solidifying its reputation as the premier brand of choice for top-tier luxury agents. For another consecutive year, a significant number of Sotheby's International Realty agents ranked among the top-producing individuals by sales volume—demonstrating the enduring strength of the brand and the exceptional caliber of agents who choose to affiliate with it. Additionally, several top-performing teams affiliated with the brand were recognized on the 2025 Top Teams by Sales Volume list.
This recognition complements the brand's continued success in attracting and retaining industry-leading talent and underscores its position as the destination of choice for high-performing real estate professionals seeking to elevate their careers in the luxury property market.
"Our continued presence at the top of these prestigious rankings reflects the unparalleled strength of our brand and the excellence of our affiliated agents," said Philip White, president and CEO, Sotheby's International Realty. "In a competitive and ever-changing market, our advisors consistently set the standard for performance and professionalism—and more luxury agents are choosing to affiliate with Sotheby's International Realty than any other brand, a testament to the trust and reputation we've built worldwide."
For the highly coveted 2025 rankings, Sotheby's International Realty secured 42 of the top 250 sales associates in the RealTrends Verified + The Thousand Individuals by Sales Volume category. This annual report ranks America's top 1,000 residential real estate agents and teams based on their 2024 sales volume and transaction sides.
2025 RealTrends Verified + The Thousand Rankings (Listed in Alphabetical Order):
Top Agents by Sales Volume
Chris Adlam
Ralph Arias
Scott Aurich
Joseph Barbieri
Lori Berris
Kim Bibb
Krissy Blake
Matt Blake
Serena Boardman
Dennis Carvajal
Daniel Casabonne
Stacie Chadwick
Binkan Cinaroglu
Richard Trey Dewey
Dan Dockray
Denise Dreyer
Robert Dullnig
Jon Flagg
Barbara Gardner
Jennifer Gilson
Harald Grant
Sheila Hall
Chris Klug
Michael LaPay
Jody Lovell
Anne Lusk
Ginger Martin
Michael Martinez
Amy McCafferty
Leslie McElwreath
Chandra Miller
Chase Mizell
Pamela Perkins
Todd Peter
Michael Rankin
Joseph Sabeh
John Shroyer
Lex Tarumianz
Mandy Welgos
Kumara Wilcoxon
Marilyn Wright
Lisa Yakulis
Top Teams by Sales Volume
The Behr Team
Brad Kappel Team
CAIN Group
Canning Properties Group
Dahler & Co.
The Dreyfus Group
The Field Team
Gregg Lynn Team
HEIDER
HRLS Partners
Huff | Vaughn | Sassi
The Michelle Thomas Team
O'Dare Boga Dobson Group
Post | Taylor Group
The Stanfield Group
The Stein Team
The Waterfront Team
Top Agents by Transactions
Sheila Hall
Anne Lusk
Lex Tarumianz
Top Teams by Transactions
Kris Weaver Real Estate Team
RPP Team
The Sotheby's International Realty brand's continued recognition in the RealTrends Verified + The Thousand Individuals by Sales Volume list attests to the brand's unwavering commitment to excellence and its unmatched ability to consistently deliver extraordinary results and attract top talent. With its renowned network of luxury agents, Sotheby's International Realty continues to set the industry standard for exceptional service and unparalleled success.
The complete RealTrends Verified + The Thousand top real estate professionals list can be found on RealTrends' website,
Sotheby's International Realty
Sotheby's International Realty was founded in 1976 as a real estate service for discerning clients of Sotheby's auction house. Today, the company's global footprint spans more than 1,100 offices located in 85 countries and territories worldwide, including 48 company-owned brokerage offices in key metropolitan and resort markets. In February 2004, Anywhere Real Estate Inc. entered a long-term strategic alliance with Sotheby's, the operator of the auction house. The agreement provided for the licensing of the Sotheby's International Realty name and the development of a franchise system. The franchise system is comprised of an affiliate network, where each office is independently owned and operated. Sotheby's International Realty supports its affiliates and agents with a host of operational, marketing, recruiting, educational and business development resources. Affiliates and agents also benefit from an association with the venerable Sotheby's auction house, established in 1744. For more information, visit www.sothebysrealty.com.
The affiliate network is operated by Sotheby's International Realty Affiliates LLC, and the company owned brokerages are operated by Sotheby's International Realty, Inc. Both entities are subsidiaries of Anywhere Real Estate Inc. (NYSE: HOUS) a global leader in real estate franchising and provider of real estate brokerage, relocation and settlement services. Both Sotheby's International Realty Affiliates LLC and Sotheby's International Realty, Inc. fully support the principles of the Fair Housing Act and the Equal Opportunity Act.
CONTACT Rachel CollettaSenior Manager, Public Relations & Communications Sotheby's International Realty 212.606.4134rachel.colletta@sothebys.realty
View original content to download multimedia:https://www.prnewswire.com/news-releases/sothebys-international-realty-leads-the-industry-once-again-in-realtrends-verified--the-thousand-rankings-302475438.html
SOURCE Sotheby's International Realty
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Engineering the Perfect Shower Squeegee: The Story Behind dancemoon JustHang Squeegee
NEW YORK, June 7, 2025 /PRNewswire/ -- dancemoon, the trailblazer in home cleaning innovation, proudly introduced its first-ever bathroom cleaning tool: the JustHang Squeegee. Designed for effortless use and stylish storage, the product officially launched worldwide on June 3 via dancemoon's website and Amazon, debuting at a special launch price of $19.99. It has been well-received on social media for its outstanding performance and uniquely innovative built-in hook, and has continued to gain traction on Amazon and the official website since its initial launch. What sets the JustHang Squeegee apart is the thoughtful design, inspired by the simple and universal natural habit of hanging things up after use. Through rounds of real-life testing and countless small tweaks, the dancemoon team turned this everyday habit into a clean, minimalist solution that blends form and function. And behind this seemingly simple tool is a deliberate design process worth sharing. How It's Made: Integrated Molded Structure: The built-in hook of JustHang Squeegee isn't a traditional after-assembly attachment. Instead, it is molded by one-piece injection molding. This process reduces breakage risk at joints, maintains minimalist lines and structural stability, prevents dirt buildup and avoids discoloration over time. The handle uses glass fiber reinforced PA66 and the scraper blade is made of hardened 45 steel, offering excellent strength and heat resistance, enabling JustHang Squeegee to withstand up to 75kg pressure without breaking. Size and Angle Validation: Based on user habit research, dancemoon designers analyzed common hanging points and user behaviors in the bathroom. Through multiple prototype tests and hanging simulations, the size and angle of the built-in hook were finely adjusted to ensure that it can be firmly fixed in places such as towel bars, glass doors and countertops, and perfectly fit the user's natural "use and hang" action. Premium Flexible Silicone: Made from high-elasticity 50 Shore A silicone, this material offers an ideal balance of flexibility and structural strength. After extensive durability testing, the dancemoon design team selected this specific hardness for its outstanding performance in wet and slippery environments, resisting deformation and cracking even with prolonged use. The result is a smoother, more efficient water-wiping experience and a significantly longer lifespan compared to traditional squeegees. Why JustHang Squeegee? Convenience: Effortless to hang anywhere even with wet hands. Versatility: Designed to fit seamlessly into various home settings, offering clean, clutter-free storage. Durability: One-piece molded construction minimizes breakage and lasts longer than traditional scrapers. To place an order, please visit dancemoon's Amazon store and Shopify. Or follow dancemoon on social media to stay updated with the latest campaigns for the new product: Instagram: Facebook: YouTube: About dancemoon Driven by a passion for innovative design, dancemoon infuses the beauty and emotion of the moon into each product. Beyond offering household tools, dancemoon combines innovation with minimalist design to create products that make household tasks simple and no longer a burden but an enjoyable part of life. With a vision to become the leading brand of minimalist lifestyle, dancemoon is committed to blending minimalism with household tools, bringing bliss into your daily life. CONTACT: info@ View original content to download multimedia: SOURCE dancemoon
Yahoo
11 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Yahoo
13 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
